After Avastin, Seeking Clarity On Progression-Free Survival Endpoints
Rather than damaging the use of progression-free survival as an endpoint in oncology clinical trials, as some have feared, the battle over Avastin’s (bevacizumab) metastatic breast cancer claim could give sponsors some clarity as to how the US FDA expects the magnitude of progression-free survival benefit to be defined.